头孢哌酮/舒巴坦钠预防老年急性呼吸衰竭感染的临床研究  

Clinical trial of cefoperazone/sulbactam in elderly patients with severe postoperative infections and hemorrhoids

作　　者：李获[1] 陶静[2] 

机构地区：[1]四川省人民医院药剂科,成都610072 [2]四川抗菌素工业研究所,成都610052

出　　处：《中国临床药理学杂志》2016年第14期1332-1333,1340,共3页The Chinese Journal of Clinical Pharmacology

基　　金：四川省卫生厅基金资助项目(100480)

摘　　要：目的探讨头孢哌酮/舒巴坦钠预防老年急性呼吸衰竭感染的有效性与安全性。方法 63例老年急性呼吸衰竭患者随机分为试验组32例和对照组31例。对照组静脉滴注盐酸环丙沙星注射液0.1 g,每日2次,试验组静脉滴注头孢哌酮/舒巴坦钠3.0 g,加入0.9%NaCl 250 m L中,每日2次;2组均治疗7 d。比较2组患者的有效率和不良反应发生率等。结果试验组治疗有效率和无效率分别为90.62%(29/32例)和9.38%(3/32例),对照组治疗有效率和无效率分别为54.84%(17/31例)和45.16%(14/31例),差异有统计学意义(P<0.05)。不良反应主要表现为恶心、头晕、食欲不振和稀便,试验组不良反应发生率为9.38%(3/32例),对照组不良反应发生率为19.35%(6/31例),差异有统计学意义(P<0.05)。结论应用头孢哌酮/舒巴坦钠预防老年急性呼吸衰竭感染有效率高,且不良反应发生率低。Objective To investigate the clinical efficacy and safety of antimicrobial drugs in elderly patients with severe hemorrhoids prevention of postoperative infection. Methods A total of 63 cases of elderly patients with severe hemorrhoids require surgical patients were randomly divided into treatment group（ n = 32） and control group（ n = 31）. Control group was intravenously given ciprofloxacin hydrochloride injection 0. 1g,2 times a day. Treatment group was intravenously given cefoperazone /sulbactam 3. 0 g added to saline 250 m L,2 times daily. All patients were treated for 7 d. The treatment effectiveness and incidence of adverse drug reactions were observed in two groups. Results The treatment efficiency and inefficiency were 90. 62%（ 29 /32） and 9. 38%（ 3 /32） in treatment group,significantly higher than 54. 84%（ 17 /31） and 45. 18%（ 14 /31）in control group（ P〈0. 05）. Adverse reactions mainly manifested as nausea,dizziness,loss of appetite and loose stools. The incidence rate of adverse drug reactions in treatment group was 9. 38%（ 3 /32）,significantly lower than 19. 35%（ 6 /31） in control group（ P〈0. 05）.Conclusion Cefoperazone / sulbactam had high efficiency and low incidence of adverse reactions in the treatment of postoperative infections in elderly patients.

关 键 词：不同抗菌药物 预防 老年急性呼吸衰竭 治疗后感染 

分 类 号：R978.1[医药卫生—药品]